Background Cancer is a well-known risk factor of preventable thromboembolic disease. This
study aims to provide guidance on the prevention and management of cancer-associated …

BACKGROUND AND OBJECTIVES: Venous thromboembolism (VTE) is commonly
encountered in the daily clinical practice. Cancer is an important VTE risk factor. Proper …

Patients with cancer are at increased risk of venous thromboembolism (vte). Anticoagulation
therapy has been shown to prevent vte; however, unique clinical circumstances in patients …

Cancer is an independent and major risk factor for venous thromboembolism (VTE), defined
by symptomatic or asymptomatic DVT, including catheter-related thrombosis (CRT), and/or …

Cancer patients are at increased risk of developing venous thromboembolism (VTE).
Guidelines recommend routine thromboprophylaxis in hospitalised acutely ill cancer …

Venous thromboembolism (VTE) is a major source of morbidity and mortality among patients
diagnosed with cancer. In addition to an increased risk of VTE, patients with cancer are at …

Venous thromboembolism is a frequent and serious complication in patients with cancer. It is
an independent prognostic factor of death in cancer patients and the second leading cause …

Venous thromboembolism (VTE) is one of the most dangerous complications of cancer.
Oncological treatment, surgeries and advanced-stage cancer are only some of the risk …

Venous thromboembolism (VTE) is a common complication among patients with cancer that
is associated with significant morbidity, mortality and health care costs. There is a significant …

Introduction Decision-making in cancer-related venous thromboembolism (VTE) is often
founded on scant lines of evidence and weak recommendations. The aim of this work is to …